Consigue una respuesta de este empleador
Tu currículum y tu carta de presentación, adaptados exactamente a lo que buscan contratar.
Olema Oncology seeks a Director, Clinical Monitoring Oversight to lead global monitoring strategy across clinical programs, ensuring GCP compliance, data integrity, and inspection readiness. You’ll oversee COMLs, CROs/FSPs, and regional teams, driving risk-based monitoring and continuous improvement in quality and efficiency.
The role is based in San Francisco or Cambridge with 10–20% travel; you will partner with Clinical Operations, Data Management, and QA to align monitoring plans with study
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. With our transformation into a fully integrated oncology company well underway, it’s an exciting time to be part of Team Olema.
Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top‑line data from OPERA‑01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second‑ or third‑line ER+/HER2‑ metastatic breast cancer (MBC), in Q1 2027 which, if positive, could lead to our first potential approval and commercial launch in 2028. OPERA‑02, our Phase 3 trial of palazestrant in combination with ribociblib in patients with frontline ER+/HER2‑ MBC, is enrolling patients. Together with its mechanism of action, pharmacokinetic properties, and the potential to demonstrate activity in both ESR1 wild‑type and mutant tumors, palazestrant could transform the metastatic breast cancer treatment paradigm and provide access to a $15 billion global market opportunity.
Our follow‑on product candidate, OP‑3136, is a potent KAT6 inhibitor with the potential to generate further value and meaningfully impact the metastatic breast cancer treatment landscape – particularly in combination with palazestrant. We recently presented encouraging Phase 1 monotherapy data from this program across multiple solid tumor types, are advancing patient enrollment in the ongoing combination arms in MBC, and expect to initiate a Phase 1 study of OP‑3136 in combination with Bayer’s darolutamide in metastatic castration‑resistant prostate cancer by the end of this year.
Aspiring to transform the metastatic treatment paradigm is an ambitious endeavor that requires a resolute approach to developing better therapies and passionate colleagues dedicated to helping the patients we serve feel better, longer. Team Olema possesses a deep commitment to a shared purpose, the sustained pursuit of excellence, cultivating the courage required to advance our programs, the drive to succeed, and a collective capacity for adaptability through learning, growth, and evolution. We are a small group of nimble self‑starters who bring consistency in our quest for the extraordinary every single day.
If you’re ready to be part of a tenacious, courageous, agile, and growing team, join us in making a profound impact, together – for our patients, for your career, and for what’s beyond.
About the Role >>> Director, Clinical Monitoring Oversight
As the Director, Clinical Monitoring Oversight reporting to the Vice President, Clinical Operations you will provide strategic and operational leadership for global clinical monitoring oversight across Olema’s clinical programs. This role ensures that clinical monitoring, whether by internal teams, through Functional Service Providers (FSPs), or outsourced to Clinical Research Organizations (CROs), is executed with high standards of quality and consistency while maintaining compliance with GCP regulations. The Director oversees Olema’s Clinical Monitoring Oversight Leads, regional monitoring and oversight teams, clinical service provider/FSP provider, and site performance. This role will develop and implement global monitoring oversight strategies and standards for Olema’s clinical monitoring execution, driving operational excellence, data integrity, and inspection readiness across all trials with an emphasis on risk-based, data driven processes. The role will adapt to evolving organizational structures, monitoring delivery models, and clinical development needs as Olema's portfolio and operational requirements change.
This role is based out of either ourSan Francisco or Cambridge office and will require 10-20% travel.
Your work will primarily encompass:
Ideal Candidate Profile >>>>
A love of challenging, important work. We are a pragmatic team, driven to imagine and develop meaningful therapies for improving lives. All employees within our company play a unique and crucial role in our success, both in accomplishing our mission and building a positive team culture. As such, we are looking for someone with the right combination of knowledge, experience, and attributes for this role.
Knowledge:
Experience:
Attributes:
The base pay range for this position is expected to be $235,000 - $250,000 annually, however the base pay offered may vary depending on location, market, job related knowledge, skills and capabilities, and experience. The total compensation package for this position also includes equity, bonus, and benefits.
We provide equal opportunity to all employees and applicants for employment and believe that great ideas and discoveries come from a mix of expertise, background, and experience. Olema is building a culture where the value of difference is celebrated.
We offer a competitive compensation and benefits package, seeking to provide an open, flexible, and friendly work environment to empower employees and provide them with a platform to develop their long‑term careers. A Summary of Benefits is available for all applicants.
Please note: Olema doesn’t accept agency resumes and is not responsible for any fees related to unsolicited resumes. Thank you.